期刊
CARDIOVASCULAR DRUG REVIEWS
卷 25, 期 2, 页码 162-174出版社
WILEY
DOI: 10.1111/j.1527-3466.2007.00012.x
关键词
angiotensin-(1-7); cancer; cardiac arrhythmias; cardiac hypertrophy; heart failure; hypertension
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051952] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL-51952] Funding Source: Medline
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据